Skip to Main Content

The $500,000 Lemelson-MIT Prize is being awarded this year to bioengineer Feng Zhang, a key developer of CRISPR genome-editing technology, the prize jury announced on Tuesday.

Although Zhang, whose lab is at the Broad Institute of MIT and Harvard, is best known for CRISPR advances such as editing genes in human and mouse cells, he wasn’t honored only for that, said bioengineer Michael Cima of MIT’s Koch Institute, the faculty director of the award.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.